GI Pharmacology · Module 2 of 8

Motility Pharmacology: Prokinetics and Antiemetics

Vomiting reflex pathways · Prokinetic agents · Antiemetic drug classes · Gastroparesis management

The vomiting center in the nucleus tractus solitarius receives four afferent inputs, each with distinct receptor pharmacology: the chemoreceptor trigger zone (CTZ, outside the blood-brain barrier, D2/5-HT3/NK1 receptors — target of dopamine antagonists, 5-HT3 antagonists, NK1 antagonists); GI vagal afferents (enterochromaffin serotonin → 5-HT3 receptors on vagal terminals — drives acute CINV 0–24 hours; blocked by 5-HT3 antagonists); vestibular nuclei (M1 muscarinic receptors — motion sickness; blocked by scopolamine); and cortical centers (anticipatory nausea; benzodiazepines).
Metoclopramide blocks D2 receptors in both the enteric nervous system (disinhibits acetylcholine release → increases antral contractility) and the CNS (antiemetic via CTZ; extrapyramidal effects via nigrostriatal blockade); black box warning: maximum 12-week use for any indication — tardive dyskinesia is often irreversible; avoid in Parkinson disease; also causes hyperprolactinemia (galactorrhea, amenorrhea); only FDA-approved drug for gastroparesis.
Domperidone (peripheral D2 antagonist only, P-gp substrate excludes from CNS): no extrapyramidal effects but prolongs QTc; not FDA-approved, expanded access only. Erythromycin (motilin receptor agonist): most potent prokinetic for acute gastroparetic crises; rapid tachyphylaxis within weeks from receptor downregulation; CYP3A4 inhibitor; QTc risk.
5-HT3 antagonists (ondansetron, palonosetron): block vagal serotonin pathway + nucleus tractus solitarius; preferred for acute CINV and PONV; ondansetron IV ≤32 mg limit (QTc risk) — use palonosetron instead when QTc prolongation is a concern (palonosetron has no cardiac channel affinity); NK1 antagonists (aprepitant, fosaprepitant): block substance P → delayed CINV days 2–5; aprepitant inhibits CYP3A4 (reduce dexamethasone dose ~50%) and induces CYP2C9 (monitor INR on warfarin).
Gastroparesis management: step 1 metoclopramide lowest dose 12-week maximum; step 2 erythromycin for acute exacerbations (expect tachyphylaxis); step 3 domperidone via expanded access if normal QTc; dietary modification and glycemic control are essential throughout; standard three-drug CINV prophylaxis for highly emetogenic chemotherapy: palonosetron + aprepitant/fosaprepitant + dexamethasone (dose-reduced for aprepitant) on day 1, then dexamethasone days 2–4.

CB1 = cannabinoid receptor type 1 · CINV = chemotherapy-induced nausea and vomiting · CTZ = chemoreceptor trigger zone · CYP3A4 = cytochrome P450 3A4 · D2 = dopamine D2 receptor · INR = international normalized ratio · M1 = muscarinic M1 receptor · NK1 = neurokinin 1 receptor · NTS = nucleus tractus solitarius · P-gp = P-glycoprotein · PONV = postoperative nausea and vomiting · QTc = corrected QT interval · 5-HT3 = serotonin type 3 receptor

Vomiting Reflex: Four Afferent Inputs

Input 1

Chemoreceptor Trigger Zone

Area postrema — outside blood-brain barrier; directly accessible to blood-borne emetogenic agents
D2, 5-HT3, NK1 receptors
Stimulated by: chemotherapy, opioids, uremic toxins, digoxin
Targets: dopamine antagonists, 5-HT3 antagonists, NK1 antagonists

Input 2

GI Vagal Afferents

Enterochromaffin cells release serotonin → 5-HT3 receptors on vagal terminals
Triggered by: chemotherapy, mucosal injury, gut distension
Dominant mechanism of acute CINV (0–24 hours)
Target: 5-HT3 receptor antagonists (ondansetron, palonosetron)

Input 3

Vestibular Nuclei

Inner ear signals via vestibular nuclei
Motion sickness, labyrinthine disorders
M1 muscarinic receptors
Target: scopolamine (transdermal patch, 72-hour duration)

Input 4

Cortical Centers

Higher centers mediating anticipatory nausea and anxiety-driven emesis
Learned associations (conditioned anticipatory response)
Targets: benzodiazepines (lorazepam) for anticipatory component; behavioral approaches

Prokinetic Agents

Drug	Mechanism	Key Advantage	Key Risk / Limitation
Metoclopramide	D2 antagonist at enteric NS (disinhibits ACh → antral contraction) + CTZ (antiemetic)	Only FDA-approved drug for gastroparesis in the US	Tardive dyskinesia (often irreversible) — black box warning; maximum 12-week use; avoid in Parkinson disease; hyperprolactinemia
Domperidone	D2 antagonist peripheral only (P-gp substrate excluded from CNS); CTZ accessible (outside BBB)	No extrapyramidal effects; no CNS D2 blockade	QTc prolongation (cardiac K⁺ channel blockade); not FDA-approved; expanded access only in US; ECG required before starting
Erythromycin	Motilin receptor agonist (subantimicrobial dose); drives phase III interdigestive contractions	Most potent prokinetic; valuable for acute gastroparetic crises IV	Rapid tachyphylaxis (receptor downregulation within days to weeks of continuous use); CYP3A4 inhibitor; QTc risk

Antiemetic Drug Classes

5-HT3 Antagonists

Ondansetron / Palonosetron

Block 5-HT3 on vagal afferent terminals + NTS neurons; interrupt peripheral serotonin pathway driving acute CINV
Acute CINV (0–24 hours) and PONV; less effective for delayed CINV
Ondansetron: QTc prolongation; IV dose ≤32 mg; monitor in hypokalemia/hypomagnesemia
Palonosetron: longer half-life, higher receptor affinity, superior for delayed CINV; no clinically significant QTc effect
Class AEs: constipation, headache

NK1 Antagonists

Aprepitant / Fosaprepitant

Block substance P at NK1 receptors in CNS → suppress delayed CINV (peaks days 2–5 post-chemotherapy)
Aprepitant: oral 3-day regimen starting day of chemotherapy; fosaprepitant: IV prodrug
Netupitant + palonosetron: fixed-dose combination capsule
Aprepitant inhibits CYP3A4 → reduce dexamethasone dose ~50% when used together
Aprepitant induces CYP2C9 → monitor INR in patients on warfarin

Other Antiemetics

D2 Blockers / Dex / Scopolamine / Dronabinol

Prochlorperazine / haloperidol: D2 blockade at CTZ; opioid-induced nausea, low-moderate emetogenicity chemotherapy; extrapyramidal + QTc risk
Dexamethasone: mechanism uncertain; adds +15–25% complete response when combined with 5-HT3 antagonists; transient hyperglycemia
Scopolamine (transdermal): M1 blocker → vestibular input; wash hands after patch (angle-closure glaucoma risk from ocular contact)
Dronabinol (CB1 agonist): refractory CINV; Schedule III; dysphoria, sedation, tachycardia; poorly tolerated in elderly
Promethazine: black box warning — contraindicated in children <2 years (respiratory depression)

Gastroparesis: Step-Through Management

Outpatient Step-Through Approach

Diabetic and Idiopathic Gastroparesis

Step 1: metoclopramide 5–10 mg before meals; lowest effective dose; document start date and 12-week stop date; review at every refill
Step 2: erythromycin 125–250 mg before meals for acute exacerbations; expect tachyphylaxis within weeks — use for short-term only
Step 3: domperidone via expanded access if normal QTc and metoclopramide not tolerated (ECG before starting)
Step 4: refer for gastric electrical stimulation evaluation if refractory
Always: optimize glycemic control (acute hyperglycemia itself inhibits gastric motility); small frequent low-fat low-fiber meals

Acute Inpatient Crisis + Standard CINV Prophylaxis

Hospital Management and Chemotherapy Regimen

Acute gastroparesis: IV hydration + electrolyte correction (hypokalemia, hypomagnesemia); IV metoclopramide 10 mg q6h; IV erythromycin 1–3 mg/kg q6–8h as adjunct; nasojejunal feeding if oral inadequate
Standard CINV regimen — highly emetogenic chemotherapy:
Day 1: palonosetron + aprepitant (or fosaprepitant) + dexamethasone (dose reduced ~50%)
Days 2–4: dexamethasone continued for delayed CINV coverage
Monitor INR if warfarin; check QTc before ondansetron in high-risk patients

Critical Rule — Metoclopramide 12-Week Maximum

Tardive dyskinesia risk rises with duration of use and cumulative dose. The FDA black box warning prohibits metoclopramide use beyond 12 weeks for any indication. When prescribing for gastroparesis, document the start date and a planned stop date at prescription initiation. Use the lowest effective dose. Inform patients of the tardive dyskinesia risk before starting and review the ongoing need at every refill. Do not prescribe to patients with Parkinson disease or prior tardive dyskinesia from any dopamine antagonist. There is no antidote for tardive dyskinesia; it is often irreversible.

Suggested References

Author / Source	Title	Publication
Katzung BG, ed.	Basic and Clinical Pharmacology, 15th ed. — Chapter on Gastrointestinal Pharmacology	McGraw-Hill; 2021
Brunton L, Knollmann B, Hilal-Dandan R, eds.	Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 14th ed.	McGraw-Hill; 2023
Hornby PJ	Central neurocircuitry associated with emesis	Am J Med. 2001;111(Suppl 8A):106S–112S
Rao AS, Camilleri M	Review article: metoclopramide and tardive dyskinesia	Aliment Pharmacol Ther. 2010;31(1):11–19
Acosta A, Camilleri M	Prokinetics in gastroparesis	Gastroenterol Clin North Am. 2015;44(1):97–111
Rojas C, Slusher BS	Pharmacological mechanisms of 5-HT3 and tachykinin NK1 receptor antagonism to prevent chemotherapy-induced nausea and vomiting	Eur J Pharmacol. 2012;684(1–3):1–7
Hesketh PJ et al.	Antiemetics: ASCO guideline update	J Clin Oncol. 2020;38(24):2782–2797
Gan TJ et al.	Fourth consensus guidelines for the management of postoperative nausea and vomiting	Anesth Analg. 2020;131(2):411–448
Camilleri M et al.	ACG clinical guideline: management of gastroparesis	Am J Gastroenterol. 2013;108(1):18–37